Fulminant Hepatic Failure
9
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
22.2%
2 terminated out of 9 trials
71.4%
-15.1% vs benchmark
22%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
TReatment for ImmUne Mediated PathopHysiology
Maternal And Fetal Outcomes in Pregnant Women With Liver Disease
A Multi-Center Trial to Study Acute Liver Failure in Adults
Study of N-Acetylcysteine in Acute Liver Failure (ALF)
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
Steroids in Fulminant Hepatitis A in the Pediatric Age Group
Cerebral Microdialysis in Patients With Fulminant Hepatic Failure
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)